On February 18th 2019, as the first country in Southeast Asia, Thailand recognized the new opportunity and legalized medical cannabis. With this decision a big chance for the country opens up, not only for its domestic health care system but also from an economic perspective.
Medical cannabis can take up between $311 – $388 million of pharma sales by 2024.
Apinya will produce full-spectrum extracts as well as isolated cannabinoid extracts for the domestic and international markets. Cannabis derived extracts with varying compositions and concentrations of THC, CBD and other cannabinoids will be developed and cultivated. Center of cultivation and production will be our facility at the campus of the University of Phayao.
With great climate conditions, competitive production costs, a very good medicinal system and the first mover advantage within Asia, Thailand is destined to become one of the economic beneficiaries from this newly emerging economic sector.